PharmaCielo Statistics
Total Valuation
PharmaCielo has a market cap or net worth of 9.68 million. The enterprise value is 24.66 million.
| Market Cap | 9.68M |
| Enterprise Value | 24.66M |
Important Dates
The last earnings date was Thursday, May 29, 2025.
| Earnings Date | May 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 187.98M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +6.83% |
| Shares Change (QoQ) | +8.17% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 172.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.00 |
| PB Ratio | -1.85 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.88 |
| EV / Sales | 9.64 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.11
| Current Ratio | 0.11 |
| Quick Ratio | 0.04 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.06 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -14.33% |
| Return on Invested Capital (ROIC) | -19.68% |
| Return on Capital Employed (ROCE) | 164.30% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.17 |
| Inventory Turnover | 1.44 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.90% in the last 52 weeks. The beta is 1.71, so PharmaCielo's price volatility has been higher than the market average.
| Beta (5Y) | 1.71 |
| 52-Week Price Change | -73.90% |
| 50-Day Moving Average | 0.04 |
| 200-Day Moving Average | 0.06 |
| Relative Strength Index (RSI) | 55.36 |
| Average Volume (20 Days) | 7,818 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PharmaCielo had revenue of 2.42 million and -6.35 million in losses. Loss per share was -0.04.
| Revenue | 2.42M |
| Gross Profit | 507,963 |
| Operating Income | -3.24M |
| Pretax Income | -6.35M |
| Net Income | -6.35M |
| EBITDA | -3.15M |
| EBIT | -3.24M |
| Loss Per Share | -0.04 |
Balance Sheet
The company has 102,818 in cash and 14.26 million in debt, giving a net cash position of -14.16 million.
| Cash & Cash Equivalents | 102,818 |
| Total Debt | 14.26M |
| Net Cash | -14.16M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -5.22M |
| Book Value Per Share | -0.03 |
| Working Capital | -13.06M |
Cash Flow
| Operating Cash Flow | -1.37M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 21.00%, with operating and profit margins of -134.06% and -262.70%.
| Gross Margin | 21.00% |
| Operating Margin | -134.06% |
| Pretax Margin | -262.70% |
| Profit Margin | -262.70% |
| EBITDA Margin | -130.12% |
| EBIT Margin | -134.06% |
| FCF Margin | n/a |
Dividends & Yields
PharmaCielo does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.83% |
| Shareholder Yield | n/a |
| Earnings Yield | -65.65% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PharmaCielo has an Altman Z-Score of -17.12 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -17.12 |
| Piotroski F-Score | 3 |